Literature DB >> 35114116

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.

Laurien J Zeverijn1, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani2, Anke A M G Pisters van Roy2, Lonneke Timmers3, T H Ly Tran3, Jolanda E de Boer3, Gijsbrecht F de Wit1, Birgit S Geurts1, Hans Gelderblom4, Henk M W Verheul5, Nicole Blijlevens6, A N Machteld Wymenga7, Ferry A L M Eskens8, Egbert F Smit9, Haiko J Bloemendal5, Emile E Voest10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35114116     DOI： 10.1016/S1470-2045(21)00707-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.

Authors:  Tobias B Polak; David G J Cucchi; Joost van Rosmalen; Carin A Uyl-de Groot; Jonathan J Darrow
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

2.  Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.

Authors:  Gennaro Ciliberto; Marco Canfora; Irene Terrenato; Chiara Agnoletto; Francesco Agustoni; Loredana Amoroso; Gustavo Baldassarre; Giuseppe Curigliano; Angelo Delmonte; Antonella De Luca; Michelangelo Fiorentino; Vanesa Gregorc; Toni Ibrahim; Chiara Lazzari; Angela Mastronuzzi; Paolo Pronzato; Armando Santoro; Giovanni Scambia; Stefania Tommasi; Andrea Vingiani; Patrizio Giacomini; Ruggero De Maria
Journal:  J Exp Clin Cancer Res       Date:  2022-10-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.